Virtual group program using continuous glucose monitors, education, and peer support for uncontrolled type 2 diabetes
Official title: The COMPASS Program: Continuous Monitoring, Peer And Structured Support for Management of Uncontrolled Type 2 Diabetes - A Prospective Single-Arm Study
Run by Whole Endo · NCT07054125 · Data updated 2026-11-12
This program will try using continuous glucose monitors together with virtual group education and peer support to help adults with type 2 diabetes and A1c over 8% lower their blood sugars and feel better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Whole Endo Industry-sponsored |
| Locations | 1 site (Asheville, North Carolina) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | August 2027 |
| Study ends | August 2028 |
| Registry record updated | July 8, 2025 |
| Trial ID | NCT07054125 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with type 2 diabetes and A1c above 8% who have a smartphone and are willing to use a CGM and attend virtual group visits are ideal candidates.
✕Probably not a fit
People with type 1 diabetes, those who are pregnant, on active cancer treatment or high-dose steroids, on dialysis for end-stage renal disease, or with dementia/major cognitive impairment (or without a smartphone/unwilling to use a CGM) are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational program enrolls adults with poorly controlled type 2 diabetes (A1c > 8%) who have a smartphone to connect with a continuous glucose monitor (CGM). Participants join virtual group visits where clinicians and peers discuss how to use and interpret CGM data, plus nutrition, physical activity, stress reduction, and habit-starting techniques. The intervention combines device-based glucose feedback, diabetes education, lifestyle counseling, and peer support rather than changes to medication mandated by the protocol. The study is run by Whole Endo with collaboration from DexCom and collects outcomes on glucose measures and quality of life over the intervention period.
Why it matters
Potential benefit: If successful, the program could help people lower average glucose and A1c and improve day-to-day diabetes self-management and quality of life.
How similar studies have gone: Prior studies have shown CGM use and structured education can improve glycemic control in type 2 diabetes, though combining virtual group visits with peer support is less extensively studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years and older * Diagnosed with type 2 diabetes mellitus Hemoglobin A1c \>8% Must have smartphone to connect with continuous glucose monitor Exclusion Criteria: * Pregnancy Use of steroids Active cancer treatment Terminal illness Dementia, mental impairment Type 1 diabetes End stage renal disease, on dialysis
Where it's running
-
Whole Endo
Asheville, North Carolina, United States Recruiting
Study contacts
- Study coordinator: Rashim Gupta, MD
- Email: rashim.gupta@wholeendo.com
- Phone: 980-349-6036
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Providing free continuous glucose monitors to improve diabetes management
This study is testing if giving free continuous glucose monitors to adults with poorly controlled type 2 diabetes can help them manage their blood sugar better and improve their quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.